Browsing ICR Divisions by author "Wilding, Christopher"
Now showing items 1-11 of 11
-
Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?
Cojocaru, E; Wilding, C; Engelman, B; Huang, P; Jones, RL (Springer Science and Business Media LLC, 2020-03-01)<jats:title>Abstract</jats:title><jats:p>Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known to be resistant to systemic cytotoxic chemotherapy ... -
Mapping the dynamic immune landscape associated with therapeutic response in soft tissue sarcoma
Huang P; Wilding, C; Huang, P (Institute of Cancer Research (University Of London), 2023-10-24)Soft tissue sarcomas (STS) are a group of rare and heterogenous cancers of unmet need. In the advanced setting, and following failure of first-line anthracycline therapy, further line therapeutic options offer limited ... -
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Chamberlain, FE; Wilding, C; Jones, RL; Huang, P (TAYLOR & FRANCIS LTD, 2019-07-03)Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ... -
Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis.
Krasny, L; Wilding, CP; Perkins, E; Arthur, A; Guljar, N; et al. (MDPI, 2022-06-13)Intravenous leiomyomatosis (IVLM) is a rare benign smooth muscle tumour that is characterised by intravenous growth in the uterine and pelvic veins. Previous DNA copy number and transcriptomic studies have shown that IVLM ... -
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
Milighetti, M; Krasny, L; Lee, ATJ; Morani, G; Szecsei, C; et al. (ELSEVIER, 2021-06-15)Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ... -
Proteomic research in sarcomas - current status and future opportunities.
Burns, J; Wilding, CP; L Jones, R; H Huang, P (ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2020-04-01)Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains ... -
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini, L; Jenks, AD; Vyse, S; Wilding, CP; Arthur, A; et al. (DOVE MEDICAL PRESS LTD, 2021-03-08)Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ... -
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
Lee, ATJ; Chew, W; Wilding, CP; Guljar, N; Smith, MJ; et al. (NATURE PORTFOLIO, 2019-10-10)The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ... -
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Wilding, CP; Elms, ML; Judson, I; Tan, A-C; Jones, RL; et al. (TAYLOR & FRANCIS LTD, 2019-10-30)Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ... -
The proteomic landscape of soft tissue sarcomas.
Burns, J; Wilding, CP; Krasny, L; Zhu, X; Chadha, M; et al. (NATURE PORTFOLIO, 2023-06-29)Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological ... -
Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding, CP; Loong, HH; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2020-06-05)PURPOSE OF REVIEW: Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas ...